PDCD1 and hepatocellular carcinoma: Nevertheless, the present results indicate that the treatment with DAAs decreased the frequency of PD-1-expressing CD4+ and CD8+ T cells and improved immune responses to HCC-specific TAA-derived peptides, suggesting the involvement of the HCV-derived F protein.